Key result
Intensity-based statin therapy replaces specific LDL-C targets across four major prevention groups.
Why the study?
The 2013 ACC/AHA blood cholesterol guidelines represented the first major revision in over a decade, shifting away from LDL-C target goals toward statin therapy intensity and raising controversy over the new risk calculator and 7.5% primary prevention threshold.
Answers are grounded in this paper and cite their sources.
This review summarizes the 2013 ACC/AHA cholesterol guidelines, highlighting the shift from LDL-C target goals to fixed-intensity statin therapy across four defined patient benefit groups.
The new American College of Cardiology/American Heart Association blood cholesterol guidelines of 2013 are the first major revision of cholesterol therapy guidance in over a decade. Commonly used low-density lipoprotein cholesterol (LDL-C) target goals have been abrogated in favor of intensity of statin therapy, more in line with data from randomized clinical trials. Four groups of adult patients have been identified from these studies who will most benefit from statins: patients with atherosclerotic cardiovascular disease (ASCVD); patients with primary elevations of LDL-C ≥ 190 mg/dL; diabetic patients between age 40 and 75 years without ASCVD whose LDL-C is between 70 and 189 mg/dL; and patients between age 40 and 75 years without ASCVD or diabetes with LDL-C between 70 and 189 mg/dL and an estimated 10-year ASCVD risk of 7.5% or higher. This last primary prevention group has engendered the most controversy because the newly recommended risk calculator may overestimate risk or the 7.5% threshold may be too low, thereby subjecting too many patients to statins unnecessarily. This review summarizes the latest guidelines and pertinent evidence, and provides case examples to help clinicians familiarize themselves with the new recommendations.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2014) conducted a review in Hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD) prevention. Intensity-based statin therapy vs. LDL-C target goal-directed therapy was evaluated. Intensity-based statin therapy replaces specific LDL-C target goals across four major patient groups, including primary prevention in adults aged 40-75 with a 10-year ASCVD risk >= 7.5%.
Synapse has enriched 10 related papers. Consider them for comparative context: